Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Administration, Intranasal
Angiotensin-Converting Enzyme 2
/ antagonists & inhibitors
Animals
Antibodies, Monoclonal
/ adverse effects
Antibodies, Neutralizing
/ administration & dosage
Apoptosis Regulatory Proteins
/ chemistry
COVID-19
/ immunology
Dose-Response Relationship, Immunologic
Female
Humans
Immunoglobulin A
/ genetics
Immunoglobulin G
/ immunology
Immunoglobulin M
/ administration & dosage
Mice
Mice, Inbred BALB C
Protein Engineering
Receptors, Virus
/ antagonists & inhibitors
SARS-CoV-2
/ classification
COVID-19 Drug Treatment
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
23
02
2021
accepted:
26
05
2021
pubmed:
4
6
2021
medline:
5
8
2021
entrez:
3
6
2021
Statut:
ppublish
Résumé
Resistance represents a major challenge for antibody-based therapy for COVID-19
Identifiants
pubmed: 34082438
doi: 10.1038/s41586-021-03673-2
pii: 10.1038/s41586-021-03673-2
pmc: PMC8742224
mid: NIHMS1761292
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Apoptosis Regulatory Proteins
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Receptors, Virus
0
spike protein, human
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
718-723Subventions
Organisme : NIAID NIH HHS
ID : R01 AI134907
Pays : United States
Organisme : NCI NIH HHS
ID : R15 CA182769
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001439
Pays : United States
Organisme : NIH HHS
ID : AI134907
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Ku, Z. et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nat. Commun. 12, 469 (2021).
doi: 10.1038/s41467-020-20789-7
Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622–625 (2021).
doi: 10.1038/s41591-021-01285-x
Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021).
doi: 10.1038/s41586-021-03398-2
Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854 (2021).
doi: 10.1126/science.abf9302
Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).
doi: 10.1038/s41586-020-2196-x
Pujadas, E. et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir. Med. 8, e70 (2020).
doi: 10.1016/S2213-2600(20)30354-4
Iwasaki, A. Exploiting mucosal immunity for antiviral vaccines. Annu. Rev. Immunol. 34, 575–608 (2016).
doi: 10.1146/annurev-immunol-032414-112315
DeFrancesco, L. COVID-19 antibodies on trial. Nat. Biotechnol. 38, 1242–1252 (2020).
doi: 10.1038/s41587-020-0732-8
Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N. Engl. J. Med. 384, 238–251 (2021).
doi: 10.1056/NEJMoa2035002
Kumar, N., Arthur, C. P., Ciferri, C. & Matsumoto, M. L. Structure of the secretory immunoglobulin A core. Science 367, 1008–1014 (2020).
doi: 10.1126/science.aaz5807
Li, Y. et al. Structural insights into immunoglobulin M. Science 367, 1014–1017 (2020).
doi: 10.1126/science.aaz5425
Vonarburg, C. et al. Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates. Respir. Res. 20, 99 (2019).
doi: 10.1186/s12931-019-1057-3
Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).
doi: 10.1126/scitranslmed.abf1555
Galimidi, R. P. et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 160, 433–446 (2015).
doi: 10.1016/j.cell.2015.01.016
ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3, e237 (2006).
doi: 10.1371/journal.pmed.0030237
Weitzner, B. D. et al. Modeling and docking of antibody structures with Rosetta. Nat. Protocols 12, 401–416 (2017).
doi: 10.1038/nprot.2016.180
Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171–1187 (2021).
doi: 10.1016/j.cell.2021.01.037
Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488 (2021).
doi: 10.1016/j.chom.2021.01.014
FDA. Fact sheet for health care providers. Emergency use authorization (EUA) of casirivimab and imdevimab, https://www.fda.gov/media/143892/download (2020).
FDA. Fact sheet for health care providers. Emergency use authorization (EUA) of bamlanivimab, https://www.fda.gov/media/143603/download (2020).
Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429–446 (2020).
doi: 10.1016/j.cell.2020.05.042
Wang, W. et al. Detection of SARS-CoV-2 in different types of clinical specimens. J. Am. Med. Assoc. 323, 1843–1844 (2020).
Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687 (2020).
doi: 10.1038/s41586-020-2852-1
Gong, S. et al. Anti-HIV IgM protects against mucosal SHIV transmission. AIDS 32, F5–F13 (2018).
doi: 10.1097/QAD.0000000000001857
Keyt, B. A., Baliga, R., Sinclair, A. M., Carroll, S. F. & Peterson, M. S. Structure, function, and therapeutic use of IgM antibodies. Antibodies 9, 53 (2020).
doi: 10.3390/antib9040053
Muruato, A. et al. Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV-2 challenge. Preprint at https://doi.org/10.1101/2021.05.03.442357 (2021).
Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 27, 841–848 (2020).
doi: 10.1016/j.chom.2020.04.004
Xie, X. et al. Engineering SARS-CoV-2 using a reverse genetic system. Nat. Protocols 16, 1761–1784 (2021).
doi: 10.1038/s41596-021-00491-8
Vorauer-Uhl, K., Wallner, J., Lhota, G., Katinger, H. & Kunert, R. IgM characterization directly performed in crude culture supernatants by a new simple electrophoretic method. J. Immunol. Methods 359, 21–27 (2010).
doi: 10.1016/j.jim.2010.05.003